GLPwatch
Victoza for Polycystic ovary syndrome
liraglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCVictoza (liraglutide) is not FDA-approved for polycystic ovary syndrome (PCOS), and any use for this condition is off-label or investigational. Listed research shows liraglutide has been studied in various trials for PCOS, including effects on weight loss, metabolic parameters, pregnancy rates, and hormonal dysfunction.
AI summary of the sources below.
| Drug | Victoza (liraglutide) |
|---|---|
| Condition | Polycystic ovary syndrome |
| Approval status | Investigational / off-label |
| Research papers | 43 |
Victoza is not FDA-approved for polycystic ovary syndrome; the research below reflects investigational or off-label study only.
Research on liraglutide for polycystic ovary syndrome (43)
- Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
- Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
- Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
- Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study.
- Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial.
- A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
- Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
- Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.
- Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.
- Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.
- The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.
- Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
- Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome.
- The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls.
- Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.
- Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome.
- Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.
- The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis.
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gut Microbiota in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome Mice: Compared Evaluation of Liraglutide and Semaglutide Intervention.
- Liraglutide mends cognitive impairment by averting Notch signaling pathway overexpression in a rat model of polycystic ovary syndrome.
- Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.
- Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
- Liraglutide Improves PCOS Symptoms in Rats by Targeting FDX1.
- Liraglutide modulates adipokine expression during adipogenesis, ameliorating obesity, and polycystic ovary syndrome in mice.
- Liraglutide administration improves hormonal/metabolic profile and reproductive features in women with HAIR-AN syndrome.